Form 4: Edwards Lifesciences CVP Sells Shares Under 10b5-1 Plan

Daniel J. Lippis, CVP JAPAC at Edwards Lifesciences Corp, sold 4,114 shares of common stock for approximately $79.46 per share under a pre-arranged trading plan.

Summary

• Daniel J. Lippis, CVP JAPAC of Edwards Lifesciences Corp (EW), disposed of 4,114 shares of common stock.
• The transaction occurred on July 28, 2025.
• The shares were sold at a weighted average price of $79.4605 per share, with individual trades ranging from $79.4500 to $79.4701.
• Following this sale, Daniel J. Lippis directly owns 22,001.9103 shares of Edwards Lifesciences common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives managing their equity holdings. While it's an insider sale, the pre-planned nature mitigates immediate negative sentiment.

Positives

• The stock sale was executed under a Rule 10b5-1 trading plan, indicating it was a pre-scheduled transaction and not based on immediate, non-public information.

Negatives

• An insider, Daniel J. Lippis, sold 4,114 shares of common stock, which represents a reduction in his direct beneficial ownership.

Future Outlook

No future outlook or guidance is provided.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context.

Stakeholder Impact

• Shareholders may note the insider sale, but the execution under a 10b5-1 plan suggests it is a pre-planned financial management decision rather than a reaction to new negative company information.

Key Dates

Recommendation

The filing details a routine insider stock sale by an executive under a pre-arranged 10b5-1 trading plan. This type of transaction is common for executives to manage personal finances and diversify holdings and does not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this disclosure.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Sale, Daniel J. Lippis, 10b5-1 Plan, Corporate Officer